Rex Bionics – More Positive Data from RAPPER II

18 August 2016: Link here. Rex Bionics Plc (AIM: RXB), the pioneer of the REX Robot technology that enhances the mobility of wheelchair users, is pleased to announce positive results from a second interim analysis of its RAPPER II clinical trial.  RAPPER II is multi-centre, international trial to evaluate the feasibility and safety of the […]

Adherium and AstraZeneca Australia Commercial Pilot Program

Melbourne, Australia, 16th August 2016 Link here.

Rex Bionics – Confirmation of Strategic Investment Maxhealth

05 August 2016: Rex Bionics plc (AIM: RXB), the pioneer of the REX Robot technology that enhances the mobility of wheelchair users, is today pleased to announce that Maxhealth Medicine Co. Ltd has now deposited £1 million in escrow in relation to its subscription for 3,333,333 ordinary shares at 30p each.  This £1 million will […]

Adherium Build Senior Leadership Team with New Chief Operating Officer and New Head of Corporate Development

Melbourne, Australia, 4 August 2016: Link here. Adherium has appointed its new Chief Operating Officer, Ross Bradding, and a new Head of Corporate Development, Julia Chambers.

AmpliPhi Biosciences Completes Enrollment of Its Investigational Phage Therapy Trial Targeting Staphylococcus aureus

Wednesday, August 3, 2016 8:45 am EDT SAN DIEGO–(BUSINESS WIRE)–Link here. AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced it has completed enrollment of its Phase 1 clinical trial to evaluate the safety of AB-SA01, its proprietary phage cocktail targeting Staphylococcus aureus (S. […]